Article - Billing and Coding: Allergy Testing (A56558)

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website.

Contractor Information

| CONTRACTOR NAME | CONTRACT TYPE | CONTRACT NUMBER | JURISDICTION | STATES |
|---|---------------|-----------------|--------------|---|
| Novitas Solutions, Inc. | A and B MAC | 04111 - MAC A | J - H | Colorado |
| Novitas Solutions, Inc. | A and B MAC | 04112 - MAC B | J - H | Colorado |
| Novitas Solutions, Inc. | A and B MAC | 04211 - MAC A | J - H | New Mexico |
| Novitas Solutions, Inc. | A and B MAC | 04212 - MAC B | J - H | New Mexico |
| Novitas Solutions, Inc. | A and B MAC | 04311 - MAC A | J - H | Oklahoma |
| Novitas Solutions, Inc. | A and B MAC | 04312 - MAC B | J - H | Oklahoma |
| Novitas Solutions, Inc. | A and B MAC | 04411 - MAC A | J - H | Texas |
| Novitas Solutions, Inc. | A and B MAC | 04412 - MAC B | J - H | Texas |
| Novitas Solutions, Inc. | A and B MAC | 04911 - MAC A | J - H | Colorado New Mexico Oklahoma Texas |
| Novitas Solutions, Inc. | A and B MAC | 07101 - MAC A | J - H | Arkansas |
| Novitas Solutions, Inc. | A and B MAC | 07102 - MAC B | J - H | Arkansas |
| Novitas Solutions, Inc. | A and B MAC | 07201 - MAC A | J - H | Louisiana |
| Novitas Solutions, Inc. | A and B MAC | 07202 - MAC B | J - H | Louisiana |
| Novitas Solutions, Inc. | A and B MAC | 07301 - MAC A | J - H | Mississippi |
| Novitas Solutions, Inc. | A and B MAC | 07302 - MAC B | J - H | Mississippi |
| Novitas Solutions, Inc. | A and B MAC | 12101 - MAC A | J - L | Delaware |
| Novitas Solutions, Inc. | A and B MAC | 12102 - MAC B | J - L | Delaware |
| Novitas Solutions, Inc. | A and B MAC | 12201 - MAC A | J - L | District of Columbia |
| Novitas Solutions, Inc. | A and B MAC | 12202 - MAC B | J - L | District of Columbia |
| Novitas Solutions, Inc. | A and B MAC | 12301 - MAC A | J - L | Maryland |
| Novitas Solutions, Inc. | A and B MAC | 12302 - MAC B | J - L | Maryland |
| Novitas Solutions, Inc. | A and B MAC | 12401 - MAC A | J - L | New Jersey |
| Novitas Solutions, Inc. | A and B MAC | 12402 - MAC B | J - L | New Jersey |
| Novitas Solutions, Inc. | A and B MAC | 12501 - MAC A | J - L | Pennsylvania |
| Novitas Solutions, Inc. Created on 01/28/2025. Pa | A and B MAC | 12502 - MAC B | J - L | Pennsylvania |

| CONTRACTOR NAME | CONTRACT TYPE | CONTRACT NUMBER | JURISDICTION | STATES |
|-------------------------|---------------|-----------------|--------------|--|
| Novitas Solutions, Inc. | A and B MAC | 12901 - MAC A | J - L | Delaware District of Columbia Maryland New Jersey Pennsylvania |

Article Information

General Information

Article ID

A56558

Article Title

Billing and Coding: Allergy Testing

Article Type

Billing and Coding

Original Effective Date

05/16/2019

Revision Effective Date

10/01/2024

Revision Ending Date

N/A

Retirement Date

N/A

CPT codes, descriptions and other data only are copyright 2024 American Medical Association. All Rights Reserved. Applicable FARS/HHSARS apply.

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

Current Dental Terminology $\ @$ 2024 American Dental Association. All rights reserved.

Copyright © 2024, the American Hospital Association, Chicago, Illinois. Reproduced with permission. No portion of the American Hospital Association (AHA) copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB\(\text{UB}\)04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at 312\(\text{SB}\)893\(\text{B816}\).

Making copies or utilizing the content of the UB□04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB□04 Manual and/or codes and descriptions; and/or making any commercial use of UB□04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. The American Hospital Association (the "AHA") has not reviewed, and is not responsible for, the completeness or accuracy of any information contained in this material, nor was the AHA or any of its affiliates, involved in the preparation of this material, or the analysis of information provided in the material. The views and/or positions presented in the material do not necessarily represent the views of the AHA. CMS and its products and services are not endorsed by the AHA or any of its affiliates.

CMS National Coverage Policy

Internet-Only Manuals (IOMs):

- CMS IOM Publication 100-04, Medicare Claims Processing Manual,
 - Chapter 12, Section 200 Allergy Testing and Immunotherapy

Social Security Act (Title XVIII) Standard References:

• Title XVIII of the Social Security Act, Section 1833(e) states that no payment shall be made to any provider of services or other person under this part unless there has been furnished such information as may be necessary in order to determine the amounts due such provider or other person under this part for the period with respect to which the amounts are being paid or for any prior period.

Article Guidance

Article Text

This Billing and Coding Article provides billing and coding guidance for Local Coverage Determination (LCD) L36241, Allergy Testing. Please refer to the LCD for reasonable and necessary requirements.

Coding Guidance

Notice: It is not appropriate to bill Medicare for services that are not covered (as described by the entire LCD) as if they are covered. When billing for non-covered services, use the appropriate modifier.

Consistent with the related LCD, CPT code 82785 (Gammaglobulin [immunoglobulin]; IgE) is not appropriate in most general allergy testing. Please refer to the LCD for details on medically reasonable and necessary guidelines.

It is not usually necessary to report CPT code 86003 (Allergen specific IgE; quantitative or semiquantitative, crude allergen extract [in vitro testing]) in addition to skin testing. Please see the related LCD for medically reasonable and necessary guidelines.

Documentation Requirements:

- 1. All documentation must be maintained in the patient's medical record and made available to the contractor upon request.
- 2. Every page of the record must be legible and include appropriate patient identification information (e.g., complete name, dates of service[s]). The documentation must include the legible signature of the physician or non-physician practitioner responsible for and providing the care to the patient.
- 3. The medical record must support the use of the selected ICD-10-CM code(s). The submitted CPT/HCPCS code must describe the service performed.
- 4. Prior to performance of allergy testing, there must be evidence in the medical record that a history has been obtained, indicating the possible presence of allergy.
 - This history should support that attempts to narrow the area of investigation were taken so that the minimal number of necessary skin tests might deliver a diagnosis.
 - The history should support that the selection of antigens was based on the patient specific history and physician examination.
- 5. The medical record must indicate which allergy test(s) were used, the interpretation(s), and measurement (in mm) of reaction size of both wheal and erythema response or a standardized grading system in vivo testing (as applicable).

Coding Information

CPT/HCPCS Codes

Group 1 Paragraph:

Note: Providers are reminded to refer to the long descriptors of the CPT codes in their CPT book.

Group 1 Codes: (10 Codes)

| CODE | DESCRIPTION |
|-------|------------------------------|
| 86003 | Allg spec ige crude xtrc ea |
| 86008 | Allg spec ige recomb ea |
| 95004 | Percut allergy skin tests |
| 95017 | Perq & icut allg test venoms |
| 95018 | Perq⁣ allg test drugs/biol |
| 95024 | Iq tests w/allergenic xtrcs |
| 95027 | Icut allergy titrate-airborn |
| 95028 | Icut allergy test-delayed |
| 0165U | Peanut allg asmt epi |
| 0178U | Peanut allg asmt epi clin rx |

Group 2 Paragraph:

N/A

Group 2 Codes: (4 Codes)

| CODE | DESCRIPTION |
|-------|-----------------------------|
| 82785 | Assay of ige |
| 86003 | Allg spec ige crude xtrc ea |
| 86008 | Allg spec ige recomb ea |
| 95070 | Bronchial allergy tests |

Group 3 Paragraph:

N/A

Group 3 Codes: (5 Codes)

| CODE | DESCRIPTION |
|-------|------------------------|
| 95044 | Allergy patch tests |
| 95052 | Photo patch test |
| 95056 | Photosensitivity tests |
| 95060 | Eye allergy tests |

| CODE | DESCRIPTION |
|-------|-------------------|
| 95065 | Nose allergy test |

Group 4 Paragraph:

N/A

Group 4 Codes: (2 Codes)

| CODE | DESCRIPTION |
|-------|------------------------------|
| 95076 | Ingest challenge ini 120 min |
| 95079 | Ingest challenge addl 60 min |

Group 5 Paragraph:

The following CPT codes are non-covered:

Group 5 Codes: (2 Codes)

| CODE | DESCRIPTION |
|-------|-----------------------------|
| 86001 | Allergen specific igg |
| 86005 | Allg spec ige multiallg scr |

CPT/HCPCS Modifiers

N/A

ICD-10-CM Codes that Support Medical Necessity

Group 1 Paragraph:

It is the provider's responsibility to select codes carried out to the highest level of specificity and selected from the ICD-10-CM code book appropriate to the year in which the service is rendered for the claim(s) submitted.

The following ICD-10-CM codes support medical necessity and provide coverage for CPT codes: **86003**, **86008**, **95004**, **95017**, **95018**, **95024**, **95027**, **95028**, **0165U**, and **0178U**.

Group 1 Codes: (209 Codes)

| CODE | DESCRIPTION |
|---------|---|
| H10.411 | Chronic giant papillary conjunctivitis, right eye |
| H10.412 | Chronic giant papillary conjunctivitis, left eye |
| H10.413 | Chronic giant papillary conjunctivitis, bilateral |
| H10.44 | Vernal conjunctivitis |
| H10.45 | Other chronic allergic conjunctivitis |
| H65.411 | Chronic allergic otitis media, right ear |

| CODE | DESCRIPTION |
|---------|---|
| H65.412 | Chronic allergic otitis media, left ear |
| H65.413 | Chronic allergic otitis media, bilateral |
| J30.1 | Allergic rhinitis due to pollen |
| J30.2 | Other seasonal allergic rhinitis |
| J30.5 | Allergic rhinitis due to food |
| J30.81 | Allergic rhinitis due to animal (cat) (dog) hair and dander |
| J30.89 | Other allergic rhinitis |
| J30.9 | Allergic rhinitis, unspecified |
| J31.0 | Chronic rhinitis |
| J32.0 | Chronic maxillary sinusitis |
| J32.1 | Chronic frontal sinusitis |
| J32.2 | Chronic ethmoidal sinusitis |
| J32.3 | Chronic sphenoidal sinusitis |
| J45.20 | Mild intermittent asthma, uncomplicated |
| J45.21 | Mild intermittent asthma with (acute) exacerbation |
| J45.22 | Mild intermittent asthma with status asthmaticus |
| J45.30 | Mild persistent asthma, uncomplicated |
| J45.31 | Mild persistent asthma with (acute) exacerbation |
| J45.32 | Mild persistent asthma with status asthmaticus |
| J45.40 | Moderate persistent asthma, uncomplicated |
| J45.41 | Moderate persistent asthma with (acute) exacerbation |
| J45.42 | Moderate persistent asthma with status asthmaticus |
| J45.50 | Severe persistent asthma, uncomplicated |
| J45.51 | Severe persistent asthma with (acute) exacerbation |
| J45.52 | Severe persistent asthma with status asthmaticus |
| J45.901 | Unspecified asthma with (acute) exacerbation |
| J45.902 | Unspecified asthma with status asthmaticus |
| J45.909 | Unspecified asthma, uncomplicated |
| J45.991 | Cough variant asthma |
| J45.998 | Other asthma |
| L20.0 | Besnier's prurigo |
| L20.81 | Atopic neurodermatitis |

| CODE | DESCRIPTION |
|----------|---|
| L20.82 | Flexural eczema |
| L20.84 | Intrinsic (allergic) eczema |
| L20.89 | Other atopic dermatitis |
| L27.2 | Dermatitis due to ingested food |
| L50.0 | Allergic urticaria |
| L50.1 | Idiopathic urticaria |
| L50.6 | Contact urticaria |
| L50.8 | Other urticaria |
| R05.3 | Chronic cough |
| T36.0X5A | Adverse effect of penicillins, initial encounter |
| T36.0X5D | Adverse effect of penicillins, subsequent encounter |
| T36.0X5S | Adverse effect of penicillins, sequela |
| T36.1X5A | Adverse effect of cephalosporins and other beta-lactam antibiotics, initial encounter |
| T36.1X5D | Adverse effect of cephalosporins and other beta-lactam antibiotics, subsequent encounter |
| T36.1X5S | Adverse effect of cephalosporins and other beta-lactam antibiotics, sequela |
| T36.4X5A | Adverse effect of tetracyclines, initial encounter |
| T36.4X5D | Adverse effect of tetracyclines, subsequent encounter |
| T36.4X5S | Adverse effect of tetracyclines, sequela |
| T36.8X5A | Adverse effect of other systemic antibiotics, initial encounter |
| T36.8X5D | Adverse effect of other systemic antibiotics, subsequent encounter |
| T36.8X5S | Adverse effect of other systemic antibiotics, sequela |
| T37.0X5A | Adverse effect of sulfonamides, initial encounter |
| T37.0X5D | Adverse effect of sulfonamides, subsequent encounter |
| T37.0X5S | Adverse effect of sulfonamides, sequela |
| T37.8X5A | Adverse effect of other specified systemic anti-infectives and antiparasitics, initial encounter |
| T37.8X5D | Adverse effect of other specified systemic anti-infectives and antiparasitics, subsequent encounter |
| T37.8X5S | Adverse effect of other specified systemic anti-infectives and antiparasitics, sequela |
| T39.015A | Adverse effect of aspirin, initial encounter |
| T39.015D | Adverse effect of aspirin, subsequent encounter |
| T39.015S | Adverse effect of aspirin, sequela |

| CODE | DESCRIPTION |
|----------|--|
| T39.1X5A | Adverse effect of 4-Aminophenol derivatives, initial encounter |
| T39.1X5D | Adverse effect of 4-Aminophenol derivatives, subsequent encounter |
| T39.1X5S | Adverse effect of 4-Aminophenol derivatives, sequela |
| T45.0X5A | Adverse effect of antiallergic and antiemetic drugs, initial encounter |
| T45.0X5D | Adverse effect of antiallergic and antiemetic drugs, subsequent encounter |
| T45.0X5S | Adverse effect of antiallergic and antiemetic drugs, sequela |
| T50.995A | Adverse effect of other drugs, medicaments and biological substances, initial encounter |
| T50.995D | Adverse effect of other drugs, medicaments and biological substances, subsequent encounter |
| T50.995S | Adverse effect of other drugs, medicaments and biological substances, sequela |
| T63.421A | Toxic effect of venom of ants, accidental (unintentional), initial encounter |
| T63.421D | Toxic effect of venom of ants, accidental (unintentional), subsequent encounter |
| T63.421S | Toxic effect of venom of ants, accidental (unintentional), sequela |
| T63.422A | Toxic effect of venom of ants, intentional self-harm, initial encounter |
| T63.422D | Toxic effect of venom of ants, intentional self-harm, subsequent encounter |
| T63.422S | Toxic effect of venom of ants, intentional self-harm, sequela |
| T63.423A | Toxic effect of venom of ants, assault, initial encounter |
| T63.423D | Toxic effect of venom of ants, assault, subsequent encounter |
| T63.423S | Toxic effect of venom of ants, assault, sequela |
| T63.424A | Toxic effect of venom of ants, undetermined, initial encounter |
| T63.424D | Toxic effect of venom of ants, undetermined, subsequent encounter |
| T63.424S | Toxic effect of venom of ants, undetermined, sequela |
| T63.431A | Toxic effect of venom of caterpillars, accidental (unintentional), initial encounter |
| T63.431D | Toxic effect of venom of caterpillars, accidental (unintentional), subsequent encounter |
| T63.431S | Toxic effect of venom of caterpillars, accidental (unintentional), sequela |
| T63.432A | Toxic effect of venom of caterpillars, intentional self-harm, initial encounter |
| T63.432D | Toxic effect of venom of caterpillars, intentional self-harm, subsequent encounter |
| T63.432S | Toxic effect of venom of caterpillars, intentional self-harm, sequela |
| T63.433A | Toxic effect of venom of caterpillars, assault, initial encounter |
| T63.433D | Toxic effect of venom of caterpillars, assault, subsequent encounter |
| T63.433S | Toxic effect of venom of caterpillars, assault, sequela |

| CODE | DESCRIPTION |
|----------|--|
| T63.434A | Toxic effect of venom of caterpillars, undetermined, initial encounter |
| T63.434D | Toxic effect of venom of caterpillars, undetermined, subsequent encounter |
| T63.434S | Toxic effect of venom of caterpillars, undetermined, sequela |
| CODE | DESCRIPTION |
| T63.441A | Toxic effect of venom of bees, accidental (unintentional), initial encounter |
| T63.441D | Toxic effect of venom of bees, accidental (unintentional), subsequent encounter |
| T63.441S | Toxic effect of venom of bees, accidental (unintentional), sequela |
| T63.442A | Toxic effect of venom of bees, intentional self-harm, initial encounter |
| T63.442D | Toxic effect of venom of bees, intentional self-harm, subsequent encounter |
| T63.442S | Toxic effect of venom of bees, intentional self-harm, sequela |
| T63.443A | Toxic effect of venom of bees, assault, initial encounter |
| T63.443D | Toxic effect of venom of bees, assault, subsequent encounter |
| T63.443S | Toxic effect of venom of bees, assault, sequela |
| T63.444A | Toxic effect of venom of bees, undetermined, initial encounter |
| T63.444D | Toxic effect of venom of bees, undetermined, subsequent encounter |
| T63.444S | Toxic effect of venom of bees, undetermined, sequela |
| T63.451A | Toxic effect of venom of hornets, accidental (unintentional), initial encounter |
| T63.451D | Toxic effect of venom of hornets, accidental (unintentional), subsequent encounter |
| T63.451S | Toxic effect of venom of hornets, accidental (unintentional), sequela |
| T63.452A | Toxic effect of venom of hornets, intentional self-harm, initial encounter |
| T63.452D | Toxic effect of venom of hornets, intentional self-harm, subsequent encounter |
| T63.452S | Toxic effect of venom of hornets, intentional self-harm, sequela |
| T63.453A | Toxic effect of venom of hornets, assault, initial encounter |
| T63.453D | Toxic effect of venom of hornets, assault, subsequent encounter |
| T63.453S | Toxic effect of venom of hornets, assault, sequela |
| T63.454A | Toxic effect of venom of hornets, undetermined, initial encounter |
| T63.454D | Toxic effect of venom of hornets, undetermined, subsequent encounter |
| T63.454S | Toxic effect of venom of hornets, undetermined, sequela |
| T63.461A | Toxic effect of venom of wasps, accidental (unintentional), initial encounter |
| T63.461D | Toxic effect of venom of wasps, accidental (unintentional), subsequent encounter |
| T63.461S | Toxic effect of venom of wasps, accidental (unintentional), sequela |
| T63.462A | Toxic effect of venom of wasps, intentional self-harm, initial encounter |

| CODE | DESCRIPTION |
|----------|--|
| T63.462D | Toxic effect of venom of wasps, intentional self-harm, subsequent encounter |
| T63.462S | Toxic effect of venom of wasps, intentional self-harm, sequela |
| T63.463A | Toxic effect of venom of wasps, assault, initial encounter |
| T63.463D | Toxic effect of venom of wasps, assault, subsequent encounter |
| T63.463S | Toxic effect of venom of wasps, assault, sequela |
| T63.464A | Toxic effect of venom of wasps, undetermined, initial encounter |
| T63.464D | Toxic effect of venom of wasps, undetermined, subsequent encounter |
| T63.464S | Toxic effect of venom of wasps, undetermined, sequela |
| T63.481A | Toxic effect of venom of other arthropod, accidental (unintentional), initial encounter |
| T63.481D | Toxic effect of venom of other arthropod, accidental (unintentional), subsequent encounter |
| T63.481S | Toxic effect of venom of other arthropod, accidental (unintentional), sequela |
| T63.482A | Toxic effect of venom of other arthropod, intentional self-harm, initial encounter |
| T63.482D | Toxic effect of venom of other arthropod, intentional self-harm, subsequent encounter |
| T63.482S | Toxic effect of venom of other arthropod, intentional self-harm, sequela |
| T63.483A | Toxic effect of venom of other arthropod, assault, initial encounter |
| T63.483D | Toxic effect of venom of other arthropod, assault, subsequent encounter |
| T63.483S | Toxic effect of venom of other arthropod, assault, sequela |
| T63.484A | Toxic effect of venom of other arthropod, undetermined, initial encounter |
| T63.484D | Toxic effect of venom of other arthropod, undetermined, subsequent encounter |
| T63.484S | Toxic effect of venom of other arthropod, undetermined, sequela |
| T78.01XA | Anaphylactic reaction due to peanuts, initial encounter |
| T78.01XD | Anaphylactic reaction due to peanuts, subsequent encounter |
| T78.01XS | Anaphylactic reaction due to peanuts, sequela |
| T78.02XA | Anaphylactic reaction due to shellfish (crustaceans), initial encounter |
| T78.02XD | Anaphylactic reaction due to shellfish (crustaceans), subsequent encounter |
| T78.02XS | Anaphylactic reaction due to shellfish (crustaceans), sequela |
| T78.03XA | Anaphylactic reaction due to other fish, initial encounter |
| T78.03XD | Anaphylactic reaction due to other fish, subsequent encounter |
| T78.03XS | Anaphylactic reaction due to other fish, sequela |
| T78.04XA | Anaphylactic reaction due to fruits and vegetables, initial encounter |

| CODE | DESCRIPTION |
|----------|---|
| T78.04XD | Anaphylactic reaction due to fruits and vegetables, subsequent encounter |
| T78.04XS | Anaphylactic reaction due to fruits and vegetables, sequela |
| T78.05XA | Anaphylactic reaction due to tree nuts and seeds, initial encounter |
| T78.05XD | Anaphylactic reaction due to tree nuts and seeds, subsequent encounter |
| T78.05XS | Anaphylactic reaction due to tree nuts and seeds, sequela |
| T78.06XA | Anaphylactic reaction due to food additives, initial encounter |
| T78.06XD | Anaphylactic reaction due to food additives, subsequent encounter |
| T78.06XS | Anaphylactic reaction due to food additives, sequela |
| T78.07XA | Anaphylactic reaction due to milk and dairy products, initial encounter |
| T78.07XD | Anaphylactic reaction due to milk and dairy products, subsequent encounter |
| T78.07XS | Anaphylactic reaction due to milk and dairy products, sequela |
| T78.08XA | Anaphylactic reaction due to eggs, initial encounter |
| T78.08XD | Anaphylactic reaction due to eggs, subsequent encounter |
| T78.08XS | Anaphylactic reaction due to eggs, sequela |
| T78.09XA | Anaphylactic reaction due to other food products, initial encounter |
| T78.09XD | Anaphylactic reaction due to other food products, subsequent encounter |
| T78.09XS | Anaphylactic reaction due to other food products, sequela |
| T78.3XXA | Angioneurotic edema, initial encounter |
| T78.3XXD | Angioneurotic edema, subsequent encounter |
| T78.3XXS | Angioneurotic edema, sequela |
| T78.40XA | Allergy, unspecified, initial encounter |
| T78.40XD | Allergy, unspecified, subsequent encounter |
| T78.40XS | Allergy, unspecified, sequela |
| T78.49XA | Other allergy, initial encounter |
| T78.49XD | Other allergy, subsequent encounter |
| T78.49XS | Other allergy, sequela |
| T80.51XA | Anaphylactic reaction due to administration of blood and blood products, initial encounter |
| T80.51XD | Anaphylactic reaction due to administration of blood and blood products, subsequent encounter |
| T80.51XS | Anaphylactic reaction due to administration of blood and blood products, sequela |
| T80.52XA | Anaphylactic reaction due to vaccination, initial encounter |

| CODE | DESCRIPTION |
|----------|--|
| T80.52XD | Anaphylactic reaction due to vaccination, subsequent encounter |
| T80.52XS | Anaphylactic reaction due to vaccination, sequela |
| T80.59XA | Anaphylactic reaction due to other serum, initial encounter |
| T80.59XD | Anaphylactic reaction due to other serum, subsequent encounter |
| T80.59XS | Anaphylactic reaction due to other serum, sequela |
| T80.61XA | Other serum reaction due to administration of blood and blood products, initial encounter |
| T80.61XD | Other serum reaction due to administration of blood and blood products, subsequent encounter |
| T80.61XS | Other serum reaction due to administration of blood and blood products, sequela |
| T80.62XA | Other serum reaction due to vaccination, initial encounter |
| T80.62XD | Other serum reaction due to vaccination, subsequent encounter |
| T80.62XS | Other serum reaction due to vaccination, sequela |
| T80.69XA | Other serum reaction due to other serum, initial encounter |
| CODE | DESCRIPTION |
| T80.69XD | Other serum reaction due to other serum, subsequent encounter |
| T80.69XS | Other serum reaction due to other serum, sequela |
| Z91.010 | Allergy to peanuts |
| Z91.011 | Allergy to milk products |
| Z91.012 | Allergy to eggs |
| Z91.013 | Allergy to seafood |
| Z91.014 | Allergy to mammalian meats |
| Z91.018 | Allergy to other foods |
| | |

Group 2 Paragraph:

It is the provider's responsibility to select codes carried out to the highest level of specificity and selected from the ICD-10-CM code book appropriate to the year in which the service is rendered for the claim(s) submitted.

The following ICD-10-CM codes support medical necessity and provide coverage for CPT codes: **82785**, **86003** (Specific IgE in-vitro Testing), **86008** and **95070**.

Group 2 Codes: (96 Codes)

| CODE | DESCRIPTION |
|-------|----------------------------------|
| B44.0 | Invasive pulmonary aspergillosis |
| J30.1 | Allergic rhinitis due to pollen |

| CODE | DESCRIPTION |
|---------|---|
| J30.2 | Other seasonal allergic rhinitis |
| J30.5 | Allergic rhinitis due to food |
| J30.81 | Allergic rhinitis due to animal (cat) (dog) hair and dander |
| J30.89 | Other allergic rhinitis |
| J30.9 | Allergic rhinitis, unspecified |
| J31.0 | Chronic rhinitis |
| J32.3 | Chronic sphenoidal sinusitis |
| J45.20 | Mild intermittent asthma, uncomplicated |
| J45.21 | Mild intermittent asthma with (acute) exacerbation |
| J45.22 | Mild intermittent asthma with status asthmaticus |
| J45.30 | Mild persistent asthma, uncomplicated |
| J45.31 | Mild persistent asthma with (acute) exacerbation |
| J45.32 | Mild persistent asthma with status asthmaticus |
| J45.40 | Moderate persistent asthma, uncomplicated |
| J45.41 | Moderate persistent asthma with (acute) exacerbation |
| J45.42 | Moderate persistent asthma with status asthmaticus |
| J45.50 | Severe persistent asthma, uncomplicated |
| J45.51 | Severe persistent asthma with (acute) exacerbation |
| J45.52 | Severe persistent asthma with status asthmaticus |
| J45.901 | Unspecified asthma with (acute) exacerbation |
| J45.902 | Unspecified asthma with status asthmaticus |
| J45.909 | Unspecified asthma, uncomplicated |
| J45.991 | Cough variant asthma |
| J45.998 | Other asthma |
| L20.82 | Flexural eczema |
| L20.84 | Intrinsic (allergic) eczema |
| L20.89 | Other atopic dermatitis |
| L50.0 | Allergic urticaria |
| L50.1 | Idiopathic urticaria |
| L50.3 | Dermatographic urticaria |
| L50.6 | Contact urticaria |
| L50.8 | Other urticaria |

| CODE | DESCRIPTION |
|----------|--|
| R05.3 | Chronic cough |
| T63.91XA | Toxic effect of contact with unspecified venomous animal, accidental (unintentional), initial encounter |
| T63.91XD | Toxic effect of contact with unspecified venomous animal, accidental (unintentional), subsequent encounter |
| T63.91XS | Toxic effect of contact with unspecified venomous animal, accidental (unintentional), sequela |
| T63.92XA | Toxic effect of contact with unspecified venomous animal, intentional self-harm, initial encounter |
| T63.92XD | Toxic effect of contact with unspecified venomous animal, intentional self-harm, subsequent encounter |
| T63.92XS | Toxic effect of contact with unspecified venomous animal, intentional self-harm, sequela |
| T63.93XA | Toxic effect of contact with unspecified venomous animal, assault, initial encounter |
| T63.93XD | Toxic effect of contact with unspecified venomous animal, assault, subsequent encounter |
| T63.93XS | Toxic effect of contact with unspecified venomous animal, assault, sequela |
| T63.94XA | Toxic effect of contact with unspecified venomous animal, undetermined, initial encounter |
| T63.94XD | Toxic effect of contact with unspecified venomous animal, undetermined, subsequent encounter |
| T63.94XS | Toxic effect of contact with unspecified venomous animal, undetermined, sequela |
| T65.811A | Toxic effect of latex, accidental (unintentional), initial encounter |
| T65.811D | Toxic effect of latex, accidental (unintentional), subsequent encounter |
| T65.811S | Toxic effect of latex, accidental (unintentional), sequela |
| T65.812A | Toxic effect of latex, intentional self-harm, initial encounter |
| T65.812D | Toxic effect of latex, intentional self-harm, subsequent encounter |
| T65.812S | Toxic effect of latex, intentional self-harm, sequela |
| T65.813A | Toxic effect of latex, assault, initial encounter |
| T65.813D | Toxic effect of latex, assault, subsequent encounter |
| T65.813S | Toxic effect of latex, assault, sequela |
| T65.814A | Toxic effect of latex, undetermined, initial encounter |
| T65.814D | Toxic effect of latex, undetermined, subsequent encounter |
| T65.814S | Toxic effect of latex, undetermined, sequela |

| CODE | DESCRIPTION |
|----------|--|
| T78.01XA | Anaphylactic reaction due to peanuts, initial encounter |
| T78.01XD | Anaphylactic reaction due to peanuts, subsequent encounter |
| T78.01XS | Anaphylactic reaction due to peanuts, sequela |
| T78.02XA | Anaphylactic reaction due to shellfish (crustaceans), initial encounter |
| T78.02XD | Anaphylactic reaction due to shellfish (crustaceans), subsequent encounter |
| T78.02XS | Anaphylactic reaction due to shellfish (crustaceans), sequela |
| T78.03XA | Anaphylactic reaction due to other fish, initial encounter |
| T78.03XD | Anaphylactic reaction due to other fish, subsequent encounter |
| T78.03XS | Anaphylactic reaction due to other fish, sequela |
| T78.04XA | Anaphylactic reaction due to fruits and vegetables, initial encounter |
| T78.04XD | Anaphylactic reaction due to fruits and vegetables, subsequent encounter |
| T78.04XS | Anaphylactic reaction due to fruits and vegetables, sequela |
| T78.05XA | Anaphylactic reaction due to tree nuts and seeds, initial encounter |
| T78.05XD | Anaphylactic reaction due to tree nuts and seeds, subsequent encounter |
| T78.05XS | Anaphylactic reaction due to tree nuts and seeds, sequela |
| T78.06XA | Anaphylactic reaction due to food additives, initial encounter |
| T78.06XD | Anaphylactic reaction due to food additives, subsequent encounter |
| T78.06XS | Anaphylactic reaction due to food additives, sequela |
| T78.07XA | Anaphylactic reaction due to milk and dairy products, initial encounter |
| T78.07XD | Anaphylactic reaction due to milk and dairy products, subsequent encounter |
| T78.07XS | Anaphylactic reaction due to milk and dairy products, sequela |
| T78.08XA | Anaphylactic reaction due to eggs, initial encounter |
| T78.08XD | Anaphylactic reaction due to eggs, subsequent encounter |
| T78.08XS | Anaphylactic reaction due to eggs, sequela |
| T78.09XA | Anaphylactic reaction due to other food products, initial encounter |
| T78.09XD | Anaphylactic reaction due to other food products, subsequent encounter |
| T78.09XS | Anaphylactic reaction due to other food products, sequela |
| T78.40XA | Allergy, unspecified, initial encounter |
| T78.40XD | Allergy, unspecified, subsequent encounter |
| T78.40XS | Allergy, unspecified, sequela |
| Z86.19* | Personal history of other infectious and parasitic diseases |
| Z91.010 | Allergy to peanuts |

| CODE | DESCRIPTION |
|---------|----------------------------|
| Z91.011 | Allergy to milk products |
| Z91.012 | Allergy to eggs |
| Z91.013 | Allergy to seafood |
| Z91.014 | Allergy to mammalian meats |
| Z91.018 | Allergy to other foods |

Group 2 Medical Necessity ICD-10-CM Codes Asterisk Explanation:

*ICD-10-CM code Z86.19 should be used for recurrent pyogenic infections.

Group 3 Paragraph:

It is the provider's responsibility to select codes carried out to the highest level of specificity and selected from the ICD-10-CM code book appropriate to the year in which the service is rendered for the claim(s) submitted.

The following ICD-10-CM codes support medical necessity and provide coverage for CPT codes: **95044**, **95052**, **95056**, **95060**, **and 95065**.

Group 3 Codes: (31 Codes)

| \ | | |
|--------|--|--|
| CODE | DESCRIPTION | |
| L23.0 | Allergic contact dermatitis due to metals | |
| L23.1 | Allergic contact dermatitis due to adhesives | |
| L23.2 | Allergic contact dermatitis due to cosmetics | |
| L23.3 | Allergic contact dermatitis due to drugs in contact with skin | |
| L23.4 | Allergic contact dermatitis due to dyes | |
| L23.5 | Allergic contact dermatitis due to other chemical products | |
| L23.6 | Allergic contact dermatitis due to food in contact with the skin | |
| L23.7 | Allergic contact dermatitis due to plants, except food | |
| L23.81 | Allergic contact dermatitis due to animal (cat) (dog) dander | |
| L23.89 | Allergic contact dermatitis due to other agents | |
| L23.9 | Allergic contact dermatitis, unspecified cause | |
| L24.0 | Irritant contact dermatitis due to detergents | |
| L24.1 | Irritant contact dermatitis due to oils and greases | |
| L24.2 | Irritant contact dermatitis due to solvents | |
| L24.3 | Irritant contact dermatitis due to cosmetics | |
| L24.4 | Irritant contact dermatitis due to drugs in contact with skin | |
| L24.5 | Irritant contact dermatitis due to other chemical products | |

| CODE | DESCRIPTION |
|--------|--|
| L24.6 | Irritant contact dermatitis due to food in contact with skin |
| L24.7 | Irritant contact dermatitis due to plants, except food |
| L24.81 | Irritant contact dermatitis due to metals |
| L24.89 | Irritant contact dermatitis due to other agents |
| L24.9 | Irritant contact dermatitis, unspecified cause |
| L25.0 | Unspecified contact dermatitis due to cosmetics |
| L25.1 | Unspecified contact dermatitis due to drugs in contact with skin |
| L25.2 | Unspecified contact dermatitis due to dyes |
| L25.3 | Unspecified contact dermatitis due to other chemical products |
| L25.4 | Unspecified contact dermatitis due to food in contact with skin |
| L25.5 | Unspecified contact dermatitis due to plants, except food |
| L25.8 | Unspecified contact dermatitis due to other agents |
| L25.9* | Unspecified contact dermatitis, unspecified cause |
| L30.8 | Other specified dermatitis |

Group 3 Medical Necessity ICD-10-CM Codes Asterisk Explanation:

*ICD-10-CM code L25.9 should be used to report contact dermatitis or contact eczema [occupational] NOS.

Group 4 Paragraph:

It is the provider's responsibility to select codes carried out to the highest level of specificity and selected from the ICD-10-CM code book appropriate to the year in which the service is rendered for the claim(s) submitted.

The following ICD-10-CM codes support medical necessity and provide coverage for CPT codes: **95076 and 95079 (Ingestion Challenge Testing).**

Group 4 Codes: (340 Codes)

| CODE | DESCRIPTION |
|----------|--|
| L27.2 | Dermatitis due to ingested food |
| T36.0X5A | Adverse effect of penicillins, initial encounter |
| T36.0X5D | Adverse effect of penicillins, subsequent encounter |
| T36.0X5S | Adverse effect of penicillins, sequela |
| T36.1X5A | Adverse effect of cephalosporins and other beta-lactam antibiotics, initial encounter |
| T36.1X5D | Adverse effect of cephalosporins and other beta-lactam antibiotics, subsequent encounter |
| T36.1X5S | Adverse effect of cephalosporins and other beta-lactam antibiotics, sequela |

| CODE | DESCRIPTION |
|----------|--|
| T36.2X5A | Adverse effect of chloramphenicol group, initial encounter |
| T36.2X5D | Adverse effect of chloramphenicol group, subsequent encounter |
| T36.2X5S | Adverse effect of chloramphenicol group, sequela |
| T36.3X5A | Adverse effect of macrolides, initial encounter |
| T36.3X5D | Adverse effect of macrolides, subsequent encounter |
| T36.3X5S | Adverse effect of macrolides, sequela |
| T36.4X5A | Adverse effect of tetracyclines, initial encounter |
| T36.4X5D | Adverse effect of tetracyclines, subsequent encounter |
| T36.4X5S | Adverse effect of tetracyclines, sequela |
| T36.5X5A | Adverse effect of aminoglycosides, initial encounter |
| T36.5X5D | Adverse effect of aminoglycosides, subsequent encounter |
| T36.5X5S | Adverse effect of aminoglycosides, sequela |
| T36.6X5A | Adverse effect of rifampicins, initial encounter |
| T36.6X5D | Adverse effect of rifampicins, subsequent encounter |
| T36.6X5S | Adverse effect of rifampicins, sequela |
| T36.7X5A | Adverse effect of antifungal antibiotics, systemically used, initial encounter |
| T36.7X5D | Adverse effect of antifungal antibiotics, systemically used, subsequent encounter |
| T36.7X5S | Adverse effect of antifungal antibiotics, systemically used, sequela |
| T36.8X5A | Adverse effect of other systemic antibiotics, initial encounter |
| T36.8X5D | Adverse effect of other systemic antibiotics, subsequent encounter |
| T36.8X5S | Adverse effect of other systemic antibiotics, sequela |
| T37.0X5A | Adverse effect of sulfonamides, initial encounter |
| T37.0X5D | Adverse effect of sulfonamides, subsequent encounter |
| T37.0X5S | Adverse effect of sulfonamides, sequela |
| T37.1X5A | Adverse effect of antimycobacterial drugs, initial encounter |
| T37.1X5D | Adverse effect of antimycobacterial drugs, subsequent encounter |
| T37.1X5S | Adverse effect of antimycobacterial drugs, sequela |
| T37.2X5A | Adverse effect of antimalarials and drugs acting on other blood protozoa, initial encounter |
| T37.2X5D | Adverse effect of antimalarials and drugs acting on other blood protozoa, subsequent encounter |
| T37.2X5S | Adverse effect of antimalarials and drugs acting on other blood protozoa, sequela |

| CODE | DESCRIPTION |
|----------|---|
| T37.3X5A | Adverse effect of other antiprotozoal drugs, initial encounter |
| T37.3X5D | Adverse effect of other antiprotozoal drugs, subsequent encounter |
| T37.3X5S | Adverse effect of other antiprotozoal drugs, sequela |
| T37.4X5A | Adverse effect of anthelminthics, initial encounter |
| T37.4X5D | Adverse effect of anthelminthics, subsequent encounter |
| T37.4X5S | Adverse effect of anthelminthics, sequela |
| T37.5X5A | Adverse effect of antiviral drugs, initial encounter |
| T37.5X5D | Adverse effect of antiviral drugs, subsequent encounter |
| T37.5X5S | Adverse effect of antiviral drugs, sequela |
| T37.8X5A | Adverse effect of other specified systemic anti-infectives and antiparasitics, initial encounter |
| T37.8X5D | Adverse effect of other specified systemic anti-infectives and antiparasitics, subsequent encounter |
| T37.8X5S | Adverse effect of other specified systemic anti-infectives and antiparasitics, sequela |
| T38.0X5A | Adverse effect of glucocorticoids and synthetic analogues, initial encounter |
| T38.0X5D | Adverse effect of glucocorticoids and synthetic analogues, subsequent encounter |
| T38.0X5S | Adverse effect of glucocorticoids and synthetic analogues, sequela |
| T38.1X5A | Adverse effect of thyroid hormones and substitutes, initial encounter |
| T38.1X5D | Adverse effect of thyroid hormones and substitutes, subsequent encounter |
| T38.1X5S | Adverse effect of thyroid hormones and substitutes, sequela |
| T38.2X5A | Adverse effect of antithyroid drugs, initial encounter |
| T38.2X5D | Adverse effect of antithyroid drugs, subsequent encounter |
| T38.2X5S | Adverse effect of antithyroid drugs, sequela |
| T38.3X5A | Adverse effect of insulin and oral hypoglycemic [antidiabetic] drugs, initial encounter |
| T38.3X5D | Adverse effect of insulin and oral hypoglycemic [antidiabetic] drugs, subsequent encounter |
| T38.3X5S | Adverse effect of insulin and oral hypoglycemic [antidiabetic] drugs, sequela |
| T38.4X5A | Adverse effect of oral contraceptives, initial encounter |
| T38.4X5D | Adverse effect of oral contraceptives, subsequent encounter |
| T38.4X5S | Adverse effect of oral contraceptives, sequela |
| T38.5X5A | Adverse effect of other estrogens and progestogens, initial encounter |
| T38.5X5D | Adverse effect of other estrogens and progestogens, subsequent encounter |

| CODE | DESCRIPTION |
|----------|--|
| T38.5X5S | Adverse effect of other estrogens and progestogens, sequela |
| T38.6X5A | Adverse effect of antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, initial encounter |
| T38.6X5D | Adverse effect of antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, subsequent encounter |
| T38.6X5S | Adverse effect of antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, sequela |
| T38.7X5A | Adverse effect of androgens and anabolic congeners, initial encounter |
| T38.7X5D | Adverse effect of androgens and anabolic congeners, subsequent encounter |
| T38.7X5S | Adverse effect of androgens and anabolic congeners, sequela |
| T38.815A | Adverse effect of anterior pituitary [adenohypophyseal] hormones, initial encounter |
| T38.815D | Adverse effect of anterior pituitary [adenohypophyseal] hormones, subsequent encounter |
| T38.815S | Adverse effect of anterior pituitary [adenohypophyseal] hormones, sequela |
| T38.895A | Adverse effect of other hormones and synthetic substitutes, initial encounter |
| T38.895D | Adverse effect of other hormones and synthetic substitutes, subsequent encounter |
| T38.895S | Adverse effect of other hormones and synthetic substitutes, sequela |
| T38.995A | Adverse effect of other hormone antagonists, initial encounter |
| T38.995D | Adverse effect of other hormone antagonists, subsequent encounter |
| T38.995S | Adverse effect of other hormone antagonists, sequela |
| T39.015A | Adverse effect of aspirin, initial encounter |
| T39.015D | Adverse effect of aspirin, subsequent encounter |
| T39.015S | Adverse effect of aspirin, sequela |
| T39.095A | Adverse effect of salicylates, initial encounter |
| T39.095D | Adverse effect of salicylates, subsequent encounter |
| T39.095S | Adverse effect of salicylates, sequela |
| T39.1X5A | Adverse effect of 4-Aminophenol derivatives, initial encounter |
| T39.1X5D | Adverse effect of 4-Aminophenol derivatives, subsequent encounter |
| T39.1X5S | Adverse effect of 4-Aminophenol derivatives, sequela |
| T39.2X5A | Adverse effect of pyrazolone derivatives, initial encounter |
| T39.2X5D | Adverse effect of pyrazolone derivatives, subsequent encounter |
| T39.2X5S | Adverse effect of pyrazolone derivatives, sequela |
| T39.315A | Adverse effect of propionic acid derivatives, initial encounter |

| CODE | DESCRIPTION |
|----------|--|
| T39.315D | Adverse effect of propionic acid derivatives, subsequent encounter |
| T39.315S | Adverse effect of propionic acid derivatives, sequela |
| T39.395A | Adverse effect of other nonsteroidal anti-inflammatory drugs [NSAID], initial encounter |
| T39.395D | Adverse effect of other nonsteroidal anti-inflammatory drugs [NSAID], subsequent encounter |
| T39.395S | Adverse effect of other nonsteroidal anti-inflammatory drugs [NSAID], sequela |
| T39.4X5A | Adverse effect of antirheumatics, not elsewhere classified, initial encounter |
| CODE | DESCRIPTION |
| T39.4X5D | Adverse effect of antirheumatics, not elsewhere classified, subsequent encounter |
| T39.4X5S | Adverse effect of antirheumatics, not elsewhere classified, sequela |
| T39.8X5A | Adverse effect of other nonopioid analgesics and antipyretics, not elsewhere classified, initial encounter |
| T39.8X5D | Adverse effect of other nonopioid analgesics and antipyretics, not elsewhere classified, subsequent encounter |
| T39.8X5S | Adverse effect of other nonopioid analgesics and antipyretics, not elsewhere classified, sequela |
| T44.3X5A | Adverse effect of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, initial encounter |
| T44.3X5D | Adverse effect of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, subsequent encounter |
| T44.3X5S | Adverse effect of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, sequela |
| T44.4X5A | Adverse effect of predominantly alpha-adrenoreceptor agonists, initial encounter |
| T44.4X5D | Adverse effect of predominantly alpha-adrenoreceptor agonists, subsequent encounter |
| T44.4X5S | Adverse effect of predominantly alpha-adrenoreceptor agonists, sequela |
| T44.5X5A | Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter |
| T44.5X5D | Adverse effect of predominantly beta-adrenoreceptor agonists, subsequent encounter |
| T44.5X5S | Adverse effect of predominantly beta-adrenoreceptor agonists, sequela |
| T44.6X5A | Adverse effect of alpha-adrenoreceptor antagonists, initial encounter |
| T44.6X5D | Adverse effect of alpha-adrenoreceptor antagonists, subsequent encounter |
| T44.6X5S | Adverse effect of alpha-adrenoreceptor antagonists, sequela |
| T44.7X5A | Adverse effect of beta-adrenoreceptor antagonists, initial encounter |

| CODE | DESCRIPTION |
|----------|---|
| T44.7X5D | Adverse effect of beta-adrenoreceptor antagonists, subsequent encounter |
| T44.7X5S | Adverse effect of beta-adrenoreceptor antagonists, sequela |
| T44.8X5A | Adverse effect of centrally-acting and adrenergic-neuron-blocking agents, initial encounter |
| T44.8X5D | Adverse effect of centrally-acting and adrenergic-neuron-blocking agents, subsequent encounter |
| T44.8X5S | Adverse effect of centrally-acting and adrenergic-neuron-blocking agents, sequela |
| T44.995A | Adverse effect of other drug primarily affecting the autonomic nervous system, initial encounter |
| T44.995D | Adverse effect of other drug primarily affecting the autonomic nervous system, subsequent encounter |
| T44.995S | Adverse effect of other drug primarily affecting the autonomic nervous system, sequela |
| T45.0X5A | Adverse effect of antiallergic and antiemetic drugs, initial encounter |
| T45.0X5D | Adverse effect of antiallergic and antiemetic drugs, subsequent encounter |
| T45.0X5S | Adverse effect of antiallergic and antiemetic drugs, sequela |
| T45.1X5A | Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter |
| T45.1X5D | Adverse effect of antineoplastic and immunosuppressive drugs, subsequent encounter |
| T45.1X5S | Adverse effect of antineoplastic and immunosuppressive drugs, sequela |
| T45.2X5A | Adverse effect of vitamins, initial encounter |
| T45.2X5D | Adverse effect of vitamins, subsequent encounter |
| T45.2X5S | Adverse effect of vitamins, sequela |
| T45.3X5A | Adverse effect of enzymes, initial encounter |
| T45.3X5D | Adverse effect of enzymes, subsequent encounter |
| T45.3X5S | Adverse effect of enzymes, sequela |
| T45.4X5A | Adverse effect of iron and its compounds, initial encounter |
| T45.4X5D | Adverse effect of iron and its compounds, subsequent encounter |
| T45.4X5S | Adverse effect of iron and its compounds, sequela |
| T45.515A | Adverse effect of anticoagulants, initial encounter |
| T45.515D | Adverse effect of anticoagulants, subsequent encounter |
| T45.515S | Adverse effect of anticoagulants, sequela |
| T45.525A | Adverse effect of antithrombotic drugs, initial encounter |

| CODE | DESCRIPTION |
|----------|---|
| T45.525D | Adverse effect of antithrombotic drugs, subsequent encounter |
| T45.525S | Adverse effect of antithrombotic drugs, sequela |
| T45.615A | Adverse effect of thrombolytic drugs, initial encounter |
| T45.615D | Adverse effect of thrombolytic drugs, subsequent encounter |
| T45.615S | Adverse effect of thrombolytic drugs, sequela |
| T45.625A | Adverse effect of hemostatic drug, initial encounter |
| T45.625D | Adverse effect of hemostatic drug, subsequent encounter |
| T45.625S | Adverse effect of hemostatic drug, sequela |
| T45.695A | Adverse effect of other fibrinolysis-affecting drugs, initial encounter |
| T45.695D | Adverse effect of other fibrinolysis-affecting drugs, subsequent encounter |
| T45.695S | Adverse effect of other fibrinolysis-affecting drugs, sequela |
| T45.7X5A | Adverse effect of anticoagulant antagonists, vitamin K and other coagulants, initial encounter |
| T45.7X5D | Adverse effect of anticoagulant antagonists, vitamin K and other coagulants, subsequent encounter |
| T45.7X5S | Adverse effect of anticoagulant antagonists, vitamin K and other coagulants, sequela |
| T45.8X5A | Adverse effect of other primarily systemic and hematological agents, initial encounter |
| T45.8X5D | Adverse effect of other primarily systemic and hematological agents, subsequent encounter |
| T45.8X5S | Adverse effect of other primarily systemic and hematological agents, sequela |
| T45.AX5A | Adverse effect of immune checkpoint inhibitors and immunostimulant drugs, initial encounter |
| T45.AX5D | Adverse effect of immune checkpoint inhibitors and immunostimulant drugs, subsequent encounter |
| T45.AX5S | Adverse effect of immune checkpoint inhibitors and immunostimulant drugs, sequela |
| T46.0X5A | Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter |
| T46.0X5D | Adverse effect of cardiac-stimulant glycosides and drugs of similar action, subsequent encounter |
| T46.0X5S | Adverse effect of cardiac-stimulant glycosides and drugs of similar action, sequela |
| T46.1X5A | Adverse effect of calcium-channel blockers, initial encounter |
| T46.1X5D | Adverse effect of calcium-channel blockers, subsequent encounter |

| CODE | DESCRIPTION |
|----------|--|
| T46.1X5S | Adverse effect of calcium-channel blockers, sequela |
| T46.2X5A | Adverse effect of other antidysrhythmic drugs, initial encounter |
| T46.2X5D | Adverse effect of other antidysrhythmic drugs, subsequent encounter |
| T46.2X5S | Adverse effect of other antidysrhythmic drugs, sequela |
| T46.3X5A | Adverse effect of coronary vasodilators, initial encounter |
| T46.3X5D | Adverse effect of coronary vasodilators, subsequent encounter |
| T46.3X5S | Adverse effect of coronary vasodilators, sequela |
| T46.4X5A | Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter |
| T46.4X5D | Adverse effect of angiotensin-converting-enzyme inhibitors, subsequent encounter |
| T46.4X5S | Adverse effect of angiotensin-converting-enzyme inhibitors, sequela |
| T46.5X5A | Adverse effect of other antihypertensive drugs, initial encounter |
| T46.5X5D | Adverse effect of other antihypertensive drugs, subsequent encounter |
| T46.5X5S | Adverse effect of other antihypertensive drugs, sequela |
| T46.6X5A | Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter |
| T46.6X5D | Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, subsequent encounter |
| T46.6X5S | Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, sequela |
| T46.7X5A | Adverse effect of peripheral vasodilators, initial encounter |
| T46.7X5D | Adverse effect of peripheral vasodilators, subsequent encounter |
| T46.7X5S | Adverse effect of peripheral vasodilators, sequela |
| T46.8X5A | Adverse effect of antivaricose drugs, including sclerosing agents, initial encounter |
| T46.8X5D | Adverse effect of antivaricose drugs, including sclerosing agents, subsequent encounter |
| T46.8X5S | Adverse effect of antivaricose drugs, including sclerosing agents, sequela |
| T46.995A | Adverse effect of other agents primarily affecting the cardiovascular system, initial encounter |
| T46.995D | Adverse effect of other agents primarily affecting the cardiovascular system, subsequent encounter |
| T46.995S | Adverse effect of other agents primarily affecting the cardiovascular system, sequela |
| T47.0X5A | Adverse effect of histamine H2-receptor blockers, initial encounter |
| T47.0X5D | Adverse effect of histamine H2-receptor blockers, subsequent encounter |
| T47.0X5S | Adverse effect of histamine H2-receptor blockers, sequela |

| CODE | DESCRIPTION |
|----------|--|
| T47.1X5A | Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter |
| T47.1X5D | Adverse effect of other antacids and anti-gastric-secretion drugs, subsequent encounter |
| CODE | DESCRIPTION |
| T47.1X5S | Adverse effect of other antacids and anti-gastric-secretion drugs, sequela |
| T47.2X5A | Adverse effect of stimulant laxatives, initial encounter |
| T47.2X5D | Adverse effect of stimulant laxatives, subsequent encounter |
| T47.2X5S | Adverse effect of stimulant laxatives, sequela |
| T47.3X5A | Adverse effect of saline and osmotic laxatives, initial encounter |
| T47.3X5D | Adverse effect of saline and osmotic laxatives, subsequent encounter |
| T47.3X5S | Adverse effect of saline and osmotic laxatives, sequela |
| T47.4X5A | Adverse effect of other laxatives, initial encounter |
| T47.4X5D | Adverse effect of other laxatives, subsequent encounter |
| T47.4X5S | Adverse effect of other laxatives, sequela |
| T47.5X5A | Adverse effect of digestants, initial encounter |
| T47.5X5D | Adverse effect of digestants, subsequent encounter |
| T47.5X5S | Adverse effect of digestants, sequela |
| T47.6X5A | Adverse effect of antidiarrheal drugs, initial encounter |
| T47.6X5D | Adverse effect of antidiarrheal drugs, subsequent encounter |
| T47.6X5S | Adverse effect of antidiarrheal drugs, sequela |
| T47.7X5A | Adverse effect of emetics, initial encounter |
| T47.7X5D | Adverse effect of emetics, subsequent encounter |
| T47.7X5S | Adverse effect of emetics, sequela |
| T47.8X5A | Adverse effect of other agents primarily affecting gastrointestinal system, initial encounter |
| T47.8X5D | Adverse effect of other agents primarily affecting gastrointestinal system, subsequent encounter |
| T47.8X5S | Adverse effect of other agents primarily affecting gastrointestinal system, sequela |
| T48.0X5A | Adverse effect of oxytocic drugs, initial encounter |
| T48.0X5D | Adverse effect of oxytocic drugs, subsequent encounter |
| T48.0X5S | Adverse effect of oxytocic drugs, sequela |
| T48.1X5A | Adverse effect of skeletal muscle relaxants [neuromuscular blocking agents], initial encounter |

| CODE | DESCRIPTION |
|----------|---|
| T48.1X5D | Adverse effect of skeletal muscle relaxants [neuromuscular blocking agents], subsequent encounter |
| T48.1X5S | Adverse effect of skeletal muscle relaxants [neuromuscular blocking agents], sequela |
| T48.295A | Adverse effect of other drugs acting on muscles, initial encounter |
| T48.295D | Adverse effect of other drugs acting on muscles, subsequent encounter |
| T48.295S | Adverse effect of other drugs acting on muscles, sequela |
| T48.3X5A | Adverse effect of antitussives, initial encounter |
| T48.3X5D | Adverse effect of antitussives, subsequent encounter |
| T48.3X5S | Adverse effect of antitussives, sequela |
| T48.4X5A | Adverse effect of expectorants, initial encounter |
| T48.4X5D | Adverse effect of expectorants, subsequent encounter |
| T48.4X5S | Adverse effect of expectorants, sequela |
| T48.5X5A | Adverse effect of other anti-common-cold drugs, initial encounter |
| T48.5X5D | Adverse effect of other anti-common-cold drugs, subsequent encounter |
| T48.5X5S | Adverse effect of other anti-common-cold drugs, sequela |
| T48.6X5A | Adverse effect of antiasthmatics, initial encounter |
| T48.6X5D | Adverse effect of antiasthmatics, subsequent encounter |
| T48.6X5S | Adverse effect of antiasthmatics, sequela |
| T48.995A | Adverse effect of other agents primarily acting on the respiratory system, initial encounter |
| T48.995D | Adverse effect of other agents primarily acting on the respiratory system, subsequent encounter |
| T48.995S | Adverse effect of other agents primarily acting on the respiratory system, sequela |
| T49.5X5A | Adverse effect of ophthalmological drugs and preparations, initial encounter |
| T49.5X5D | Adverse effect of ophthalmological drugs and preparations, subsequent encounter |
| T49.5X5S | Adverse effect of ophthalmological drugs and preparations, sequela |
| T50.0X5A | Adverse effect of mineralocorticoids and their antagonists, initial encounter |
| T50.0X5D | Adverse effect of mineralocorticoids and their antagonists, subsequent encounter |
| T50.0X5S | Adverse effect of mineralocorticoids and their antagonists, sequela |
| T50.1X5A | Adverse effect of loop [high-ceiling] diuretics, initial encounter |
| T50.1X5D | Adverse effect of loop [high-ceiling] diuretics, subsequent encounter |
| T50.1X5S | Adverse effect of loop [high-ceiling] diuretics, sequela |

| CODE | DESCRIPTION |
|----------|--|
| T50.2X5A | Adverse effect of carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, initial encounter |
| T50.2X5D | Adverse effect of carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, subsequent encounter |
| T50.2X5S | Adverse effect of carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, sequela |
| T50.3X5A | Adverse effect of electrolytic, caloric and water-balance agents, initial encounter |
| T50.3X5D | Adverse effect of electrolytic, caloric and water-balance agents, subsequent encounter |
| T50.3X5S | Adverse effect of electrolytic, caloric and water-balance agents, sequela |
| T50.4X5A | Adverse effect of drugs affecting uric acid metabolism, initial encounter |
| T50.4X5D | Adverse effect of drugs affecting uric acid metabolism, subsequent encounter |
| T50.4X5S | Adverse effect of drugs affecting uric acid metabolism, sequela |
| T50.5X5A | Adverse effect of appetite depressants, initial encounter |
| T50.5X5D | Adverse effect of appetite depressants, subsequent encounter |
| T50.5X5S | Adverse effect of appetite depressants, sequela |
| T50.7X5A | Adverse effect of analeptics and opioid receptor antagonists, initial encounter |
| T50.7X5D | Adverse effect of analeptics and opioid receptor antagonists, subsequent encounter |
| T50.7X5S | Adverse effect of analeptics and opioid receptor antagonists, sequela |
| T50.8X5A | Adverse effect of diagnostic agents, initial encounter |
| T50.8X5D | Adverse effect of diagnostic agents, subsequent encounter |
| T50.8X5S | Adverse effect of diagnostic agents, sequela |
| T50.A15A | Adverse effect of pertussis vaccine, including combinations with a pertussis component, initial encounter |
| T50.A15D | Adverse effect of pertussis vaccine, including combinations with a pertussis component, subsequent encounter |
| T50.A15S | Adverse effect of pertussis vaccine, including combinations with a pertussis component, sequela |
| T50.A25A | Adverse effect of mixed bacterial vaccines without a pertussis component, initial encounter |
| T50.A25D | Adverse effect of mixed bacterial vaccines without a pertussis component, subsequent encounter |
| T50.A25S | Adverse effect of mixed bacterial vaccines without a pertussis component, sequela |
| T50.A95A | Adverse effect of other bacterial vaccines, initial encounter |

| CODE | DESCRIPTION |
|----------|--|
| T50.A95D | Adverse effect of other bacterial vaccines, subsequent encounter |
| T50.A95S | Adverse effect of other bacterial vaccines, sequela |
| T50.B95A | Adverse effect of other viral vaccines, initial encounter |
| T50.B95D | Adverse effect of other viral vaccines, subsequent encounter |
| T50.B95S | Adverse effect of other viral vaccines, sequela |
| T50.Z15A | Adverse effect of immunoglobulin, initial encounter |
| T50.Z15D | Adverse effect of immunoglobulin, subsequent encounter |
| T50.Z15S | Adverse effect of immunoglobulin, sequela |
| T50.Z95A | Adverse effect of other vaccines and biological substances, initial encounter |
| T50.Z95D | Adverse effect of other vaccines and biological substances, subsequent encounter |
| T50.Z95S | Adverse effect of other vaccines and biological substances, sequela |
| T50.995A | Adverse effect of other drugs, medicaments and biological substances, initial encounter |
| T50.995D | Adverse effect of other drugs, medicaments and biological substances, subsequent encounter |
| T50.995S | Adverse effect of other drugs, medicaments and biological substances, sequela |
| T78.01XA | Anaphylactic reaction due to peanuts, initial encounter |
| T78.01XD | Anaphylactic reaction due to peanuts, subsequent encounter |
| T78.01XS | Anaphylactic reaction due to peanuts, sequela |
| T78.02XA | Anaphylactic reaction due to shellfish (crustaceans), initial encounter |
| T78.02XD | Anaphylactic reaction due to shellfish (crustaceans), subsequent encounter |
| T78.02XS | Anaphylactic reaction due to shellfish (crustaceans), sequela |
| CODE | DESCRIPTION |
| T78.03XA | Anaphylactic reaction due to other fish, initial encounter |
| T78.03XD | Anaphylactic reaction due to other fish, subsequent encounter |
| T78.03XS | Anaphylactic reaction due to other fish, sequela |
| T78.04XA | Anaphylactic reaction due to fruits and vegetables, initial encounter |
| T78.04XD | Anaphylactic reaction due to fruits and vegetables, subsequent encounter |
| T78.04XS | Anaphylactic reaction due to fruits and vegetables, sequela |
| T78.05XA | Anaphylactic reaction due to tree nuts and seeds, initial encounter |
| T78.05XD | Anaphylactic reaction due to tree nuts and seeds, subsequent encounter |
| T78.05XS | Anaphylactic reaction due to tree nuts and seeds, sequela |

| CODE | DESCRIPTION |
|----------|--|
| T78.06XA | Anaphylactic reaction due to food additives, initial encounter |
| T78.06XD | Anaphylactic reaction due to food additives, subsequent encounter |
| T78.06XS | Anaphylactic reaction due to food additives, sequela |
| T78.07XA | Anaphylactic reaction due to milk and dairy products, initial encounter |
| T78.07XD | Anaphylactic reaction due to milk and dairy products, subsequent encounter |
| T78.07XS | Anaphylactic reaction due to milk and dairy products, sequela |
| T78.08XA | Anaphylactic reaction due to eggs, initial encounter |
| T78.08XD | Anaphylactic reaction due to eggs, subsequent encounter |
| T78.08XS | Anaphylactic reaction due to eggs, sequela |
| T78.09XA | Anaphylactic reaction due to other food products, initial encounter |
| T78.09XD | Anaphylactic reaction due to other food products, subsequent encounter |
| T78.09XS | Anaphylactic reaction due to other food products, sequela |
| T78.1XXA | Other adverse food reactions, not elsewhere classified, initial encounter |
| T78.1XXD | Other adverse food reactions, not elsewhere classified, subsequent encounter |
| T78.1XXS | Other adverse food reactions, not elsewhere classified, sequela |
| Z88.0 | Allergy status to penicillin |
| Z88.1 | Allergy status to other antibiotic agents |
| Z88.2 | Allergy status to sulfonamides |
| Z88.3 | Allergy status to other anti-infective agents |
| Z88.4 | Allergy status to anesthetic agent |
| Z88.5 | Allergy status to narcotic agent |
| Z88.6 | Allergy status to analgesic agent |
| Z88.7 | Allergy status to serum and vaccine |
| Z88.8 | Allergy status to other drugs, medicaments and biological substances |
| Z91.010 | Allergy to peanuts |
| Z91.011 | Allergy to milk products |
| Z91.012 | Allergy to eggs |
| Z91.013 | Allergy to seafood |
| Z91.014 | Allergy to mammalian meats |
| Z91.018 | Allergy to other foods |

ICD-10-CM Codes that DO NOT Support Medical Necessity

Group 1 Paragraph:

All those not listed under the "ICD-10-CM Codes that Support Medical Necessity" section of this article.

Group 1 Codes: (1 Code)

| CODE | DESCRIPTION |
|-------|----------------|
| XX000 | Not Applicable |

ICD-10-PCS Codes

N/A

Additional ICD-10 Information

N/A

Bill Type Codes

Contractors may specify Bill Types to help providers identify those Bill Types typically used to report this service. Absence of a Bill Type does not guarantee that the article does not apply to that Bill Type. Complete absence of all Bill Types indicates that coverage is not influenced by Bill Type and the article should be assumed to apply equally to all claims.

| CODE | DESCRIPTION |
|------|----------------|
| 999x | Not Applicable |

Revenue Codes

Contractors may specify Revenue Codes to help providers identify those Revenue Codes typically used to report this service. In most instances Revenue Codes are purely advisory. Unless specified in the article, services reported under other Revenue Codes are equally subject to this coverage determination. Complete absence of all Revenue Codes indicates that coverage is not influenced by Revenue Code and the article should be assumed to apply equally to all Revenue Codes.

| CODE | DESCRIPTION |
|-------|----------------|
| 99999 | Not Applicable |

Other Coding Information

N/A

Revision History Information

| REVISION HISTORY DATE | REVISION HISTORY NUMBER | REVISION HISTORY EXPLANATION | |
|-----------------------------|-------------------------------|--|--|
| 10/01/2024 | R15 | Article revised and published on 10/24/2024 effective for dates of service on and after 10/01/2024 to reflect the Annual ICD-10-CM Code Updates. The following ICD-10-CM codes have been added to the 'ICD-10-CM Codes that Support Medical Necessity' section for 'Group 4 Codes': T45.AX5A, T45.AX5D and T45.AX5S. | |
| 08/01/2024 | R14 | Article revised and published on 08/01/2024 effective for dates of service on and after 06/10/2024. The following ICD-10 codes have been added: J30.9 and R05.3 to Group 1 and J30.1, J30.2, J30.81, J30.89, J30.9, and R05.3 to Group 2. | |
| 07/01/2024 | R13 | Article revised and published on 07/18/2024 effective for dates of service on and after 07/01/2024. For the following CPT code, the short description was changed: 95024. This revision is in response to the July CPT/HCPCS quarterly update. | |
| 04/01/2024 | R12 | Article revised and published on 04/04/2024 effective for dates of service on and after 04/01/2024 to reflect the April Quarterly CPT/HCPCS Code Update. For the following CPT/HCPCS code either the short description and/or the long description was changed: 95024. Depending on which description is used in this article, there may not be any change in how the code displays in the document. | |
| 01/13/2023 | R11 | Article revised and published on 02/23/2023 effective for dates of service on and after 01/13/2023 in response to an inquiry. The following ICD-10-CM codes have been added to the `ICD-10-CM Codes that Support Medical Necessity' section for `Group 1 Codes' and `Group 2 Codes': J30.5, J32.3, J45.901, J45.902, J45.909, T78.40XA, T78.40XD, T78.40XS, Z91.010, Z91.011, Z91.012, Z91.013, Z91.014, and Z91.018. | |
| 01/01/2022 | R10 | Article revised and published on 02/17/2022 effective for dates of service on and after 09/03/2021. CPT codes 0165U and 0178U have been added to the 'CPT/HCPCS Codes' section for 'Group 1 Codes' and to the 'ICD-10-CM Codes that Support Medical Necessity' section for 'Group 1 Paragraph'. | |
| 01/01/2022 | R9 | Article revised and published on 1/20/2022 effective for dates of service on and after 01/01/2022 to reflect the Annual HCPCS/CPT Code Updates. For the following CPT code either the short description and/or the long description was changed. Depending on which description is used in this article, there may not be any change in how the code displays: 95070 in Group 2 Codes. | |
| 07/11/2021 | R8 | Article revised and published on 11/18/2021 effective for dates of service on and after 07/11/2021 in response to an inquiry. The following ICD-10-CM codes have been added to the 'ICD-10-CM Codes that Support Medical Necessity' section for 'Group 4 Codes': T36.0X5A, T36.0X5D, T36.0X5S, T36.1X5A, T36.1X5D, T36.1X5S, T36.2X5A, T36.2X5D, T36.2X5S, T36.3X5A, T36.3X5D, T36.3X5S, T36.4X5A, T36.4X5D, T36.4X5S, T36.5X5A, T36.5X5D, T36.5X5S, | |

| REVISION HISTORY DATE | REVISION HISTORY NUMBER | REVISION HISTORY EXPLANATION | |
|-----------------------------|-------------------------------|--|--|
| | | T36.8X5A, T36.8X5D, T36.8X5S, T37.0X5A, T37.0X5D, T37.0X5S, T37.1X5A, T37.1X5D, T37.1X5S, T37.2X5A, T37.2X5D, T37.2X5S, T37.3X5A, T37.3X5D, T37.3X5S, T37.4X5A, T37.4X5D, T37.5X5A, T37.5X5A, T37.5X5D, T37.5X5S, T37.8X5A, T37.8X5D, T38.0X5D, T38.0X5D, T38.0X5D, T38.1X5D, T38.1X5D, T38.4X5D, T38.4X5D, T38.4X5D, T38.4X5D, T38.4X5D, T38.4X5D, T38.5X5A, T38.5X5D, T39.05D, T39.05D, T39.05D, T39.05D, T39.05D, T39.1X5D, T39.1X5D, T39.1X5D, T39.1X5D, T39.1X5D, T39.1X5D, T39.1X5D, T39.1X5D, T39.1X5D, T39.395D, T39.395D, T39.2X5D, T39.2X5D, T39.2X5D, T39.3X5D, T44.5X5D, T45.5X5D, T46.5X5D, T | |
| 07/11/2021 | R7 | Article revised and published on 10/21/2021 effective for dates of service on and after 07/11/2021 in response to an inquiry. The following ICD-10 codes have been added to the 'ICD-10-CM Codes that Support Medical Necessity' section for 'Group 4 Codes': Z88.0, Z88.1, Z88.2, Z88.3, Z88.4, Z88.5, Z88.6, Z88.7, Z88.8, Z91.010, Z91.011, Z91.012, Z91.013, Z91.014, and Z91.018. | |
| 07/11/2021 | R6 | Draft article posted on 01/14/2021. Article effective for dates of service on and after 07/11/2021. | |
| 10/01/2020 | R5 | Article revised and published on 10/01/2020 effective for dates of service on and after | |

| REVISION HISTORY DATE | REVISION HISTORY NUMBER | REVISION HISTORY EXPLANATION | |
|-----------------------------|-------------------------------|--|--|
| | | 10/01/2020 to reflect the Annual ICD-10-CM Code Updates. The following ICD-10-CM code(s) have undergone a descriptor change: Z88.1, Z88.2, Z88.3, Z88.4, Z88.5, Z88.6, Z88.7, Z88.8, Z88.9 for Group 1 Codes and Z88.1, Z88.2, Z88.3, Z88.4, Z88.5, Z88.6, Z88.7, Z88.8 for Group 4 Codes. Minor formatting changes made through the coding section. | |
| 07/01/2020 | R4 | Article revised and published on 07/30/2020 effective for dates of service on and after 07/01/2020, CPT code 0178U has been added to CPT code group 1 and ICD-10 group 2 paragraph. In addition, under CPT/HCPCS codes, Group 1 Codes, 0165U has a descriptor change due to July HCPCS code updates. | |
| 07/01/2020 | R3 | Article revised and published on 06/25/2020 effective for dates of service on and after 07/01/2020, as a non-discretionary update to remove CPT code 86001 from Group 2 CPT codes group. Minor formatting changes have been made. | |
| 04/01/2020 | R2 | Article revised and published on 04/30/2020 effective for dates of service on and after 04/01/2020, consistent with CMS Change Request 11681. CPT code 0165U was added to code group 1 and to the ICD-10 group 2 paragraph. Formatting changes have also been made. | |
| 10/17/2019 | R1 | Article revised and published on 10/17/2019 effective for dates of service on and after 10/01/2019 to reflect the Annual ICD-10-CM Code Updates. The following ICD-10-CM code has undergone a descriptor change: J44.0. An asterisk has been added next to Z86.19 in ICD-10 Code Group 2 code table and the note regarding this code has been moved from the Group 2 paragraph to the asterisk explanation. Please note, system changes have been made to our articles in response to CMS Change Request 10901. The Coding Section has been reordered and new sections for CPT/HCPCS Modifiers and Other Coding Information have been added. | |

Associated Documents

Related Local Coverage Documents

Articles

A58750 - Response to Comments: Allergy Testing (MCD Archive Site)

LCDs

L36241 - Allergy Testing

Related National Coverage Documents

N/A

Statutory Requirements URLs

N/A

Created on 01/28/2025. Page 33 of 34

Rules and Regulations URLs

N/A

CMS Manual Explanations URLs

N/A

Other URLs

N/A

Public Versions

| UPDATED ON | EFFECTIVE DATES | STATUS | | |
|---|-------------------------|------------------------------------|--|--|
| Some older versions have been archived. Please visit the MCD Archive Site to retrieve them. | | | | |
| 10/18/2024 | 10/01/2024 - N/A | Currently in Effect (This Version) | | |
| 07/25/2024 | 08/01/2024 - 09/30/2024 | Superseded | | |
| 07/12/2024 | 07/01/2024 - 07/31/2024 | Superseded | | |
| 03/27/2024 | 04/01/2024 - 06/30/2024 | Superseded | | |
| 02/17/2023 | 01/13/2023 - 03/31/2024 | Superseded | | |

Keywords

N/A